IceCure ProSense Breast Cancer Cryoablation: Promising 12-Month Data Reported at EUSOBI 2026
IceCure ProSense breast cancer cryoablation: the company reports 97.5% 12-month response in 40 patients. Study design and safety data were not disclosed.
Read More
Vantis Vascular Wins CrossFAST 6F FDA Clearance: Powerful New Option for Complex PCI
CrossFAST 6F FDA clearance adds a larger-lumen microcatheter for complex PCI. It is a new configuration; no outcome data were reported.
Oorja Bio Begins ORJ-001 Pulmonary Fibrosis Trial: A Critical Test for a New Approach
ORJ-001 pulmonary fibrosis trial begins: Oorja Bio screens its first patient in Phase 2. The drug is experimental and no efficacy results exist yet.
Soufflé Therapeutics $135 Million Funding: Powerful Boost for RNA Drugs
Soufflé Therapeutics $135 million funding backs RNA drugs for FSHD and heart failure. The treatments are experimental; no new human data were reported.
FDA Backs Proposed Stem Cell Trial for Treatment-Resistant Crohn’s Disease
StemSmart Crohn’s disease clinical trial gets positive FDA pre-IND feedback on 6 of 7 questions; a viral safety issue remains. Not a marketing approval.
Lasix ONYU Home Study: 18 of 21 Heart Failure Patients Avoided Admission
Early data say 18 of 21 heart failure patients were treated at home with Lasix ONYU. What hospital leaders can and cannot conclude from a single-arm study.
Castle Biosciences Data Show Barrett’s Risk Test Shifts Surveillance Plans
Castle Biosciences says TissueCypher changed Barrett’s management for 96% of cohort patients. Where the test fits in surveillance and what is unproven.
Envoy’s Fully Implanted Cochlear Implant Files Second FDA Module
Envoy Medical has filed 2 of 4 FDA modules for its investigational Acclaim implant. A status board of what is done, pending and still undisclosed.
Sun Pharma Board Caps Debenture Raise at ₹10,000 Crore
Sun Pharma will raise up to ₹10,000 crore via NCDs, down from ₹15,000 crore, as Gautam Doshi quits. NCD terms explained, ratings and open questions.